



Press Release

**MEDIAN Technologies  
To Participate in the 2014 ASCO Annual Conference**

*MEDIAN will demonstrate its Lesion Management Solutions (LMS)  
and discuss the results of its abstract at Booth #4125, Hall B*

**Sophia Antipolis, France – May 28, 2014** – MEDIAN Technologies (ALMDT), a leading medical imaging software solutions developer and a service provider for image interpretation and management in oncology clinical trials, today announced its participation in the 2014 ASCO annual conference, to be held next May 30 – June 3, in Chicago, IL, USA (exhibition dates: May 31-June 2).

During ASCO, the world's premier oncology conference, representatives from MEDIAN will be present at Booth #4125, Hall B to give demonstrations of their Lesion Management Solutions software and to discuss their abstract, ['Volume-based Response Evaluations with Consensual Lesion Selection Using Cloud Solutions in Clinical Trials'](#). The use of lesion volume is considered as a promising alternative to RECIST (Response Evaluation Criteria in Solid Tumors) to make tumor measurements more accurate, consistent, and for earlier detection of changes. The pilot study conducted by MEDIAN aimed at evaluating the effects of target (TL) and new lesions (NL) selection on volume-based response (VBR) assessments. The study was carried out on lung cancer patients CT scans. Images were analyzed according to RECIST and VBR criteria by two oncologists (Japan and Scotland) and one radiologist (France) by using cloud solutions (MEDIAN Technologies). This study provides additional evidence about the benefit of using VBR over RECIST. The use of cloud solutions showed to be an interesting and feasible strategy for standardizing response evaluations and reducing variability in multi-center clinical trials. This type of initiative is of great importance for increasing consistency in the production of trial results.



**ALMDT**  
**LISTED**  
**NYSE**  
**ALTERNEXT**

**About MEDIAN Technologies:** MEDIAN Technologies develops medical imaging software and services dedicated to oncology clinical trials, cancer screening, and clinical practice. MEDIAN Technologies standardizes and automates the interpretation of medical images in oncology to optimize the diagnosis of cancer patients and the assessment of their response to therapy. MEDIAN serves two primary markets: drug development and patient care. MEDIAN has a strategic partnership with the world’s largest CRO (Contract Research Organization) to offer integrated imaging services for clinical trials to biopharma sponsors worldwide, and a strategic partnership with Canon to develop new imaging technologies, and to address the patient care market.

Founded in 2002, MEDIAN Technologies is based in Sophia-Antipolis, France, and has a US subsidiary in Boston. MEDIAN has a global reach and actively works with clinical sites located in Asia, Europe, North and South America, and Australia.

MEDIAN has received the label "Innovative company" by the BPI and is listed on Euronext Paris' Alternext market (ISIN: FR0011049824, ticker: ALMDT). The company is eligible for the PEA PME SME equity savings plan setup.

For more information on MEDIAN, please visit: [www.mediantechologies.com](http://www.mediantechologies.com)

*“We are committed to the improvement of cancer patient outcomes through innovation in medical imaging and quality execution for better screening, diagnosis, and monitoring of patients.”*

## Contacts

### MEDIAN Technologies

Fredrik Brag, CEO  
+33 4 92 90 65 82  
[fredrik.brag@mediantechnologies.com](mailto:fredrik.brag@mediantechnologies.com)

### Press

**ALIZE RP**  
Caroline Carmagnol  
Sayuli Nishioka  
+ 33 1 70 22 53 86  
[median@alizerp.com](mailto:median@alizerp.com)

### Investors

**ACTIFIN**  
Anaïs de Scitivaux  
+ 33 1 56 88 11 14  
[adescitivaux@actifin.fr](mailto:adescitivaux@actifin.fr)